# FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE
> **ANDA213087** · Abbreviated New Drug Application (Generic) · Sponsor: CIPLA · Approved 2026-07-27
## Drug
- **FDA Application Number:** ANDA213087
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE
- **Generic name:** FLUTICASONE PROPIONATE AND SALMETEROL
- **Active ingredients:** FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE
- **Dosage form:** POWDER
- **Route:** INHALATION
- **Marketing status:** Prescription
- **Sponsor:** CIPLA
- **Manufacturer:** Cipla USA Inc.
- **First approval:** 2026-07-27
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213087)
---
*MORVS · CC0 1.0*